2014 Generics Sales: $6.5 billion +10%
Worldwide Market Share: 8.8%
2014 was a big year for Mylan ($MYL). In July, it agreed to nab a big chunk of Abbott Laboratories' ($ABT) drug business, comprising more than 100 specialty and branded generic pharma products in cardio/metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women's and men's health. At the time, the company said the deal would double its sales in Europe--one of its generics hubs, along with the U.S., Canada, India, Australia, Japan, New Zealand and Brazil--and expand its total revenues by about 30%.
The added sales heft would help with planned launches of copies of Teva's ($TEVA) multiple sclerosis star Copaxone and GlaxoSmithKline's ($GSK) Advair, Mylan said at the time. Neither of those have yet to materialize, however; Mylan's Copaxone copy is still awaiting FDA approval, and in the meantime, Novartis' ($NVS) Sandoz has launched a version of the blockbuster.
Mylan launched plenty of other products that year, though, including a version of Pfizer ($PFE) arthritis med Celebrex. Both Mylan and Teva rolled out knockoffs of the $2.56 billion seller last December after a U.S. court struck down a patent-office decision to reissue a key IP shield on the drug. Pfizer prevailed over Mylan earlier in the year, though, in October trumpeting a U.S. District Court's decision that the company had infringed its patents on kidney cancer med Sutent.
2014 held other ups and down for Mylan, as well. In September, it became one of a handful of countries with a license to bring Gilead's ($GILD) hepatitis C behemoth Sovaldi to 91 developing countries at a low cost. It got its wrist slapped in July, though, when the EU's third pay-for-delay action hit Mylan, Servier and others.
Mylan also found itself amid deal rumors that didn't pan out. Early in 2014, word on the street was that it was eyeing Pfizer's brand-new established products unit, created after the company's Jan. 1 three-way division; that unit has so far stayed with Pfizer, with no bidders publicly reaching out. Sweden's Meda also turned Mylan down, leaving analysts thinking the company could jump on Stada or Mallinckrodt ($MNK) before it eventually tied up with Abbott.
Mylan hasn't stopped trying to bulk up since then, either. It's currently fighting a hostile takeover war against target Perrigo ($PRGO)--a company it first went after when it was trying to dodge its own hostile pursuit from generics leader Teva. -- Carly Helfand (email | Twitter)
Special Report: Pharma's top 10 M&A deals of 2014 - Mylan/Abbott Laboratories established products
Another Pfizer blockbuster bites the dust as Celebrex generics roll
Pfizer turns back Mylan's patent challenge to Sutent
Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets
Mylan beefs up outside the U.S. with $5.3B deal for Abbott drug business
EU's third pay-for-delay action nails Servier, Teva, Mylan and others
Stymied by Meda, deal-hungry Mylan could jump on Stada or Mallinckrodt